

DNA VACCINES: TECHNOLOGIES AND GLOBAL MARKETS



BIO067B
July 2014

Jon Evans
Project Analyst

ISBN: 1-56965-883-8



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
INTENDED AUDIENCE	3
SCOPE OF REPORT	3
<i>TABLE A SCOPE OF REPORT</i>	3
METHODOLOGY	4
INFORMATION SOURCES	4
RELATED BCC RESEARCH REPORTS	4
ANALYST CREDENTIALS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
<i>SUMMARY TABLE GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, 2013-2019 (\$ MILLIONS)</i>	7
CHAPTER 3 OVERVIEW	11
INTRODUCTION	11
DNA VACCINE TECHNOLOGIES COVERED IN THIS REPORT	11
<i>TABLE 1 SCOPE OF THIS REPORT</i>	11
GLOBAL MARKET FOR DNA VACCINES	12
<i>TABLE 2 GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)</i>	12
<i>TABLE 3 GLOBAL VALUE OF HUMAN DNA VACCINE MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	12
FORCES DRIVING DNA VACCINE MARKET GROWTH	13
<i>TABLE 4 DNA VACCINE INDUSTRY GROWTH DRIVING FORCES</i>	13
LIFE CYCLE STATUS OF DNA VACCINE TECHNOLOGIES	14
<i>TABLE 5 LIFE CYCLE STAGE OF VACCINE TYPES</i>	14
COMMERCIAL STATUS OF DNA VACCINE TECHNOLOGIES	14
<i>TABLE 6 COMMERCIAL STATUS OF DNA VACCINES</i>	14
DNA VACCINE INDUSTRY	15
<i>TABLE 7 DNA VACCINE INDUSTRY STRUCTURE</i>	15
CHAPTER 4 DNA VACCINE TECHNOLOGIES	18
HISTORY	18
<i>TABLE 8 DNA VACCINE HISTORY</i>	19
THE HUMAN IMMUNE SYSTEM	20
<i>TABLE 9 COMPONENTS OF THE IMMUNE SYSTEM</i>	20
VACCINES	22
VACCINE EVOLUTION	22
<i>FIGURE 1 EVOLUTION OF VACCINE TECHNOLOGIES</i>	22
VACCINE TYPES	23

TOPIC	PAGE NO.
<i>TABLE 10 VACCINE TYPES</i>	23
Technology Life Cycle Stage of Vaccine Types	24
<i>TABLE 11 TECHNOLOGY LIFE CYCLE STAGE OF VACCINE TYPES</i>	24
DNA VACCINES	25
INTRODUCTION	25
<i>FIGURE 2 MECHANISM OF ACTION OF A DNA VACCINE</i>	25
CHANGING VACCINE PARADIGM	26
<i>TABLE 12 CHANGING VACCINE PARADIGM</i>	26
<i>TABLE 13 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES</i>	27
<i>FIGURE 3 SAFETY AND EFFICACY PROFILE OF DNA VERSUS VIRAL-VECTOR VACCINES</i>	29
FUNCTION AND SCOPE OF DNA VACCINES	29
<i>FIGURE 4 DNA VACCINE FUNCTION AND MARKET SCOPE</i>	29
<i>TABLE 14 EMERGING COMPETITIVE LANDSCAPE FOR DNA VACCINES</i>	31
CANCER DNA VACCINES	31
<i>TABLE 15 CANCER VACCINE TYPES</i>	32
DNA VACCINE TECHNOLOGY VALUE CHAIN	33
<i>FIGURE 5 DNA VACCINE TECHNOLOGY VALUE CHAIN</i>	33
<i>TABLE 16 TECHNOLOGY DRIVERS FOR DNA VACCINE VALUE CHAIN</i>	34
Antigen Discovery	35
Plasmid Design	35
<i>TABLE 17 PLASMID DESIGN OBJECTIVES</i>	35
<i>TABLE 18 WAYS TO OPTIMIZE MAMMALIAN GENE EXPRESSION IN PLASMID DNA</i>	36
Plasmid Manufacture	37
<i>FIGURE 6 CONVENTIONAL AND PLASMID DNA VACCINE PRODUCTION PROCESS</i>	38
<i>TABLE 19 DNA PLASMID QUALITY COMPARISON</i>	38
Delivery Technologies	39
<i>TABLE 20 COMPARISON OF DNA DELIVERY TECHNOLOGIES</i>	39
Uncomplexed pDNA	39
Electroporation	40
<i>FIGURE 7 EP PROCESS SCHEMATIC</i>	41
Liposomes	41
Gold Particles	42
Nanoparticles	42
Bacterial Ghosts	43
Bacteriophages	43
Viruses	43
<i>TABLE 21 IN VIVO VIRAL VECTOR TECHNOLOGIES COMPARED</i>	44
Targeting Technologies	45
<i>FIGURE 8 STRATEGIES FOR TARGETING DENDRITIC CELLS</i>	46
Adjuvant Technologies	46
<i>TABLE 22 DNA VACCINE ADJUVANT TECHNOLOGIES</i>	46
DNA VACCINE TECHNOLOGY NEEDS	47
<i>TABLE 23 TECHNOLOGY NEEDS FOR DNA VACCINES</i>	48
CHAPTER 5 DNA VACCINE APPLICATIONS	51
RESEARCH TOOL APPLICATIONS	51
CLINICAL APPLICATIONS	51

TOPIC	PAGE NO.
OVERVIEW TO DNA VACCINE CLINICAL TRIALS PROCESS	51
TABLE 24 DNA VACCINE DEVELOPMENT FLOW SHEET	52
TABLE 25 DNA VACCINE PRECLINICAL DEVELOPMENT STEPS	53
FIGURE 9 FUTURE VACCINE CLINICAL TRIALS OVERVIEW	53
DNA VACCINE CLINICAL TRIALS SUMMARY	55
TABLE 26 DNA VACCINES CLINICAL TRIALS SUMMARY BY STARTING YEAR, AS OF APRIL 2014	55
TABLE 27 DNA VACCINE CLINICAL PHASE I TRIALS SUMMARY, AS OF APRIL 2014	56
TABLE 28 DNA VACCINE CLINICAL PHASE I/II TRIALS SUMMARY, AS OF APRIL 2014	59
TABLE 29 DNA VACCINE CLINICAL PHASE II TRIALS SUMMARY, AS OF APRIL 2014	60
TABLE 30 DNA VACCINE CLINICAL PHASE II/III TRIALS SUMMARY, AS OF APRIL 2014	61
TABLE 31 DNA VACCINE CLINICAL PHASE III TRIALS SUMMARY, AS OF APRIL 2014	62
TABLE 32 DNA VACCINE CLINICAL PHASE IV TRIALS SUMMARY, AS OF APRIL 2014	64
CANCER DNA VACCINE CLINICAL TRIALS	65
TABLE 33 DNA VACCINE CANCER CLINICAL TRIALS SUMMARY, AS OF APRIL 2014	65
Melanoma	67
INFECTIOUS DISEASE DNA VACCINES	68
TABLE 34 INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF APRIL 2014	68
HSV	73
HPV	73
Influenza	74
HBV	75
Japanese Encephalitis	76
CMV	76
HIV	77
ALLERGY AND AUTOIMMUNE DISEASE	78
TABLE 35 INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF APRIL 2014	78
BIODEFENSE DNA VACCINES	78
ANIMAL HEALTH DNA VACCINES	79
CHAPTER 6 DNA VACCINE INDUSTRY	82
VACCINE INDUSTRY STRUCTURAL SHIFTS	82
TABLE 36 VACCINE INDUSTRY STRUCTURAL SHIFTS	82
INDUSTRY STRUCTURE	83
TABLE 37 VACCINE INDUSTRY STRUCTURE: TRADITIONAL VERSUS EMERGING	83
FIGURE 10 MARKETING OF APPROVED VACCINES IN THE UNITED STATES, 2014 (%)	84
TABLE 38 COMPARISON OF VACCINES AND PHARMACEUTICALS BUSINESSES	85
DNA VACCINE INDUSTRY COMPETITORS	87
TABLE 39 DNA VACCINE INDUSTRY COMPETITOR POSITION	87
DNA VACCINE COMMERCIAL VALUE CHAIN	88
FIGURE 11 DNA VACCINE COMMERCIAL VALUE CHAIN	89
DNA VACCINE COMPETITOR STRATEGIC POSITIONING	89
TABLE 40 LARGE PHARMA VACCINE COMPANY STRATEGIC FOCUS	89
TABLE 41 INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS	90
TABLE 42 INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC MARKET FOCUS	91
TABLE 43 SPECIALIZED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS	93

TOPIC	PAGE NO.
RESEARCH & DEVELOPMENT FOCUS	94
TABLE 44 ASTELLAS PHARMA INC. OPEN CLINICAL TRIALS, AS OF APRIL 2014	94
TABLE 45 BAVARIAN NORDIC OPEN CLINICAL TRIALS, AS OF APRIL 2014	94
TABLE 46 BEIJING CENTER FOR DISEASE CONTROL AND PREVENTION; MUNICIPAL SCIENCE & TECHNOLOGY COMMISSION OPEN CLINICAL TRIALS, AS OF APRIL 2014	95
TABLE 47 CITY OF HOPE MEDICAL CENTER, NATIONAL CANCER INSTITUTE (NCI) OPEN CLINICAL TRIALS, AS OF APRIL 2014	95
TABLE 48 DYNAVAX TECHNOLOGIES CORPORATION OPEN CLINICAL TRIALS, AS OF APRIL 2014	95
TABLE 49 GLAXOSMITHKLINE OPEN CLINICAL TRIALS, AS OF APRIL 2014	96
TABLE 50 IMPERIAL COLLEGE LONDON OPEN CLINICAL TRIALS, AS OF APRIL 2014	96
TABLE 51 MERCK SHARP & DOHME OPEN CLINICAL TRIALS, AS OF APRIL 2014	97
TABLE 52 NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) OPEN CLINICAL TRIALS, AS OF APRIL 2014	97
TABLE 53 NATIONAL TAIWAN UNIVERSITY HOSPITAL OPEN CLINICAL TRIALS, AS OF APRIL 2014	98
TABLE 54 SANOFI OPEN CLINICAL TRIALS, AS OF APRIL 2014	98
TABLE 55 SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER OPEN CLINICAL TRIALS, AS OF APRIL 2014	98
TABLE 56 U.S. ARMY MEDICAL RESEARCH OPEN CLINICAL TRIALS, AS OF APRIL 2014	99
TABLE 57 UNIVERSITY OF COLORADO OPEN CLINICAL TRIALS, AS OF APRIL 2014	99
TABLE 58 UNIVERSITY OF OXFORD OPEN CLINICAL TRIALS, AS OF APRIL 2014	100
TABLE 59 UNIVERSITY OF WISCONSIN OPEN CLINICAL TRIALS, AS OF APRIL 2014	100
INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES	100
TABLE 60 INDUSTRY ACQUISITIONS AND MERGERS, 2006-2014	100
TABLE 61 DNA VACCINE STRATEGIC ALLIANCES	102
CHAPTER 7 DNA VACCINE MARKETS	105
GROWTH DRIVING FORCES	105
TABLE 62 DNA VACCINE INDUSTRY GROWTH DRIVING FORCES	105
MARKET FORECASTS	106
OVERVIEW	106
TABLE 63 GLOBAL VALUE OF PHARMACEUTICAL MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	106
DNA VACCINE MARKETS BY END USE	107
TABLE 64 GLOBAL VALUE OF DNA VACCINES BY END USE, THROUGH 2019 (\$ MILLIONS)	107
DNA VACCINE RESEARCH TOOLS MARKETS	108
TABLE 65 GLOBAL VALUE OF DNA VACCINES RESEARCH TOOLS MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	108
DNA VACCINE CLINICAL MARKETS	108
TABLE 66 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	109
Strategic Positioning	109
FIGURE 12 DNA VACCINE STRATEGIC MARKET GRID	109
Allergies	110
TABLE 67 DNA VACCINE ALLERGY MARKET OPPORTUNITIES	110
Cancer Therapeutics	110
TABLE 68 CAUSE OF DEATH, WORLDWIDE, 2004 AND 2030 (% OF ALL DEATHS)	111

TOPIC	PAGE NO.
Infectious Diseases	111
DNA CANCER VACCINES MARKET	111
<i>TABLE 69 GLOBAL VALUE OF CANCER CLINICAL DNA VACCINES BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	112
<i>TABLE 70 DNA VACCINE CANCER MARKET OPPORTUNITIES</i>	112
Melanoma	114
Solid Tumors (Including Ovarian, Breast and Small-Cell Lung Cancer)	114
Pancreatic Cancer	114
INFECTIOUS DISEASE DNA VACCINE MARKETS	114
<i>TABLE 71 GLOBAL VALUE OF INFECTIOUS DISEASE CLINICAL DNA VACCINES MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	115
CMV	115
HBV	116
HPV	116
HCV	117
HIV	117
ANIMAL HEALTH DNA VACCINE MARKETS	118
<i>TABLE 72 GLOBAL VALUE OF ANIMAL HEALTH CLINICAL DNA VACCINES MARKET, BY INDICATION, THROUGH 2019 (\$ MILLIONS)</i>	118
Canine Melanoma	119
Equine West Nile Virus	119
Leishmaniasis	119
Feline Leukemia Virus	120
Fish Vaccine Adjuvants	120
BIODEFENSE DNA VACCINE MARKETS	120
<i>TABLE 73 GLOBAL VALUE OF BIODEFENSE CLINICAL DNA VACCINES MARKET, BY END USE, THROUGH 2019 (\$ MILLIONS)</i>	121
DNA VACCINE MARKETS BY DELIVERY TECHNOLOGY	123
<i>TABLE 74 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY DELIVERY TECHNOLOGY, THROUGH 2019 (\$ MILLIONS)</i>	124
DNA VACCINE MARKET BY FORMAT AND FUNCTION	124
<i>TABLE 75 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY VACCINE FORMAT, THROUGH 2019 (\$ MILLIONS)</i>	125
<i>TABLE 76 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY FUNCTION, THROUGH 2019 (\$ MILLIONS)</i>	125
DNA VACCINES MARKET BY GEOGRAPHICAL REGION	125
<i>TABLE 77 GLOBAL VALUE OF DNA VACCINES MARKET, BY GEOGRAPHICAL REGION, THROUGH 2019 (\$ MILLIONS)</i>	126
CHAPTER 8 COMPANY PROFILES	128
ADIMMUNE	128
ADVANCED BIOSCIENCE LABORATORIES INC.	128
ALDEVRON LLC	129
ALTEA THERAPEUTICS	129
ALTHEA TECHNOLOGIES INC.	130
ANGES MG INC.	130
AVAX TECHNOLOGIES	131
BAVARIAN NORDIC A/S	131
BIGDNA, LTD.	132

TOPIC	PAGE NO.
BIOJECT MEDICAL TECHNOLOGIES INC.	133
BTX HARVARD APPARATUS	134
CHANGCHUN BAIKE PHARMACEUTICAL CO. LTD.	134
CHRONTECH PHARMA	134
COBRA BIOMANUFACTURING PLC	135
CRUCCELL	136
CYTRX CORP.	137
DENDREON CORP.	137
DYNAVAX TECHNOLOGIES	138
EUROVACC FOUNDATION, THE	138
FIT BIOTECH OYJ PLC	139
GENEART AG	140
GENETIC IMMUNITY	141
GENEXINE	142
GENOMIDEA INC.	143
GENOVAC GMBH	144
GENVEC INC.	145
GEOVAX LABS	145
GLAXOSMITHKLINE	146
GREENPAK BIOTECH LTD.	148
HENDERSON MORLEY PLC	148
ICHOR MEDICAL SYSTEMS INC.	149
IGXBIO INC.	150
IMMUNOMIC THERAPEUTICS INC.	150
IMMUNOVACCINE INC.	151
IN CELL ART	152
INDIAN IMMUNOLOGICALS	153
INOVIO	154
INVIVOGEN	156
JUVARIS BIOTHERAPEUTICS INC.	156
LENTIGEN CORP.	157
MANKIND CORP.	157
MERCK	158
<i>TABLE 78 MERCK VACCINE PRODUCTS</i>	159
MERIAL LTD.	159
MOGAM BIOTECHNOLOGY RESEARCH INSTITUTE	160
MOLOGEN AG	160
MULTIMERIC BIOTHERAPEUTICS INC.	161
NATURE TECHNOLOGY CORP.	162
NIH VACCINE RESEARCH CENTER	162
NOVARTIS	163
OXFORD BIOMEDICA PLC	164
PFIZER	164
PLASMIDFACTORY GMBH & CO.	165
PROFECTUS BIOSCIENCES INC.	166
QED BIOSCIENCE INC.	167
SANOFI-AVENTIS	168

TOPIC	PAGE NO.
STATENS SERUM INSTITUT	169
SUPRATEK PHARMA	170
TOLERION INC.	170
VALNEVA SE	171
VAXGEN INC.	171
VAXIION THERAPEUTICS INC.	172
VAXONCO INC.	173
VGX PHARMACEUTICALS LLC	173
VGXI INC.	174
VICAL INC.	174
VIROMED CO. LTD.	175
XENETIC BIOSCIENCE INC.	176
<i>TABLE 79 COMPANIES WITH ACTIVE DNA VACCINE CLINICAL TRIALS</i>	176

LIST OF TABLES

TABLE HEADING	PAGE NO.
TABLE A SCOPE OF REPORT	3
SUMMARY TABLE GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 SCOPE OF THIS REPORT	11
TABLE 2 GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	12
TABLE 3 GLOBAL VALUE OF HUMAN DNA VACCINE MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	12
TABLE 4 DNA VACCINE INDUSTRY GROWTH DRIVING FORCES	13
TABLE 5 LIFE CYCLE STAGE OF VACCINE TYPES	14
TABLE 6 COMMERCIAL STATUS OF DNA VACCINES	14
TABLE 7 DNA VACCINE INDUSTRY STRUCTURE	15
TABLE 8 DNA VACCINE HISTORY	19
TABLE 9 COMPONENTS OF THE IMMUNE SYSTEM	20
TABLE 10 VACCINE TYPES	23
TABLE 11 TECHNOLOGY LIFE CYCLE STAGE OF VACCINE TYPES	24
TABLE 12 CHANGING VACCINE PARADIGM	26
TABLE 13 ADVANTAGES AND DISADVANTAGES OF DNA VACCINES	27
TABLE 14 EMERGING COMPETITIVE LANDSCAPE FOR DNA VACCINES	31
TABLE 15 CANCER VACCINE TYPES	32
TABLE 16 TECHNOLOGY DRIVERS FOR DNA VACCINE VALUE CHAIN	34
TABLE 17 PLASMID DESIGN OBJECTIVES	35
TABLE 18 WAYS TO OPTIMIZE MAMMALIAN GENE EXPRESSION IN PLASMID DNA	36
TABLE 19 DNA PLASMID QUALITY COMPARISON	38
TABLE 20 COMPARISON OF DNA DELIVERY TECHNOLOGIES	39
TABLE 21 IN VIVO VIRAL VECTOR TECHNOLOGIES COMPARED	44
TABLE 22 DNA VACCINE ADJUVANT TECHNOLOGIES	46
TABLE 23 TECHNOLOGY NEEDS FOR DNA VACCINES	48
TABLE 24 DNA VACCINE DEVELOPMENT FLOW SHEET	52
TABLE 25 DNA VACCINE PRECLINICAL DEVELOPMENT STEPS	53
TABLE 26 DNA VACCINES CLINICAL TRIALS SUMMARY BY STARTING YEAR, AS OF APRIL 2014	55
TABLE 27 DNA VACCINE CLINICAL PHASE I TRIALS SUMMARY, AS OF APRIL 2014	56
TABLE 28 DNA VACCINE CLINICAL PHASE I/II TRIALS SUMMARY, AS OF APRIL 2014	59
TABLE 29 DNA VACCINE CLINICAL PHASE II TRIALS SUMMARY, AS OF APRIL 2014	60
TABLE 30 DNA VACCINE CLINICAL PHASE II/III TRIALS SUMMARY, AS OF APRIL 2014	61
TABLE 31 DNA VACCINE CLINICAL PHASE III TRIALS SUMMARY, AS OF APRIL 2014	62
TABLE 32 DNA VACCINE CLINICAL PHASE IV TRIALS SUMMARY, AS OF APRIL 2014	64
TABLE 33 DNA VACCINE CANCER CLINICAL TRIALS SUMMARY, AS OF APRIL 2014	65
TABLE 34 INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF APRIL 2014	68
TABLE 35 INFECTIOUS DISEASES DNA VACCINES CLINICAL TRIALS, AS OF APRIL 2014	78
TABLE 36 VACCINE INDUSTRY STRUCTURAL SHIFTS	82
TABLE 37 VACCINE INDUSTRY STRUCTURE: TRADITIONAL VERSUS EMERGING	83
TABLE 38 COMPARISON OF VACCINES AND PHARMACEUTICALS BUSINESSES	85
TABLE 39 DNA VACCINE INDUSTRY COMPETITOR POSITION	87
TABLE 40 LARGE PHARMA VACCINE COMPANY STRATEGIC FOCUS	89

TABLE HEADING	PAGE NO.
TABLE 41 INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS	90
TABLE 42 INTEGRATED BIOTECHNOLOGY COMPANY STRATEGIC MARKET FOCUS	91
TABLE 43 SPECIALIZED BIOTECHNOLOGY COMPANY STRATEGIC FOCUS	93
TABLE 44 ASTELLAS PHARMA INC. OPEN CLINICAL TRIALS, AS OF APRIL 2014	94
TABLE 45 BAVARIAN NORDIC OPEN CLINICAL TRIALS, AS OF APRIL 2014	94
TABLE 46 BEIJING CENTER FOR DISEASE CONTROL AND PREVENTION; MUNICIPAL SCIENCE & TECHNOLOGY COMMISSION OPEN CLINICAL TRIALS, AS OF APRIL 2014	95
TABLE 47 CITY OF HOPE MEDICAL CENTER, NATIONAL CANCER INSTITUTE (NCI) OPEN CLINICAL TRIALS, AS OF APRIL 2014	95
TABLE 48 DYNAVAX TECHNOLOGIES CORPORATION OPEN CLINICAL TRIALS, AS OF APRIL 2014	95
TABLE 49 GLAXOSMITHKLINE OPEN CLINICAL TRIALS, AS OF APRIL 2014	96
TABLE 50 IMPERIAL COLLEGE LONDON OPEN CLINICAL TRIALS, AS OF APRIL 2014	96
TABLE 51 MERCK SHARP & DOHME OPEN CLINICAL TRIALS, AS OF APRIL 2014	97
TABLE 52 NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) OPEN CLINICAL TRIALS, AS OF APRIL 2014	97
TABLE 53 NATIONAL TAIWAN UNIVERSITY HOSPITAL OPEN CLINICAL TRIALS, AS OF APRIL 2014	98
TABLE 54 SANOFI OPEN CLINICAL TRIALS, AS OF APRIL 2014	98
TABLE 55 SIDNEY KIMMEL COMPREHENSIVE CANCER CENTER OPEN CLINICAL TRIALS, AS OF APRIL 2014	98
TABLE 56 U.S. ARMY MEDICAL RESEARCH OPEN CLINICAL TRIALS, AS OF APRIL 2014	99
TABLE 57 UNIVERSITY OF COLORADO OPEN CLINICAL TRIALS, AS OF APRIL 2014	99
TABLE 58 UNIVERSITY OF OXFORD OPEN CLINICAL TRIALS, AS OF APRIL 2014	100
TABLE 59 UNIVERSITY OF WISCONSIN OPEN CLINICAL TRIALS, AS OF APRIL 2014	100
TABLE 60 INDUSTRY ACQUISITIONS AND MERGERS, 2006-2014	100
TABLE 61 DNA VACCINE STRATEGIC ALLIANCES	102
TABLE 62 DNA VACCINE INDUSTRY GROWTH DRIVING FORCES	105
TABLE 63 GLOBAL VALUE OF PHARMACEUTICAL MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	106
TABLE 64 GLOBAL VALUE OF DNA VACCINES BY END USE, THROUGH 2019 (\$ MILLIONS)	107
TABLE 65 GLOBAL VALUE OF DNA VACCINES RESEARCH TOOLS MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	108
TABLE 66 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY APPLICATION, THROUGH 2019 (\$ MILLIONS)	109
TABLE 67 DNA VACCINE ALLERGY MARKET OPPORTUNITIES	110
TABLE 68 CAUSE OF DEATH, WORLDWIDE, 2004 AND 2030 (% OF ALL DEATHS)	111
TABLE 69 GLOBAL VALUE OF CANCER CLINICAL DNA VACCINES BY INDICATION, THROUGH 2019 (\$ MILLIONS)	112
TABLE 70 DNA VACCINE CANCER MARKET OPPORTUNITIES	112
TABLE 71 GLOBAL VALUE OF INFECTIOUS DISEASE CLINICAL DNA VACCINES MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	115
TABLE 72 GLOBAL VALUE OF ANIMAL HEALTH CLINICAL DNA VACCINES MARKET, BY INDICATION, THROUGH 2019 (\$ MILLIONS)	118
TABLE 73 GLOBAL VALUE OF BIODEFENSE CLINICAL DNA VACCINES MARKET, BY END USE, THROUGH 2019 (\$ MILLIONS)	121
TABLE 74 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY DELIVERY TECHNOLOGY, THROUGH 2019 (\$ MILLIONS)	124

TABLE HEADING	PAGE NO.
TABLE 75 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY VACCINE FORMAT, THROUGH 2019 (\$ MILLIONS)	125
TABLE 76 GLOBAL VALUE OF CLINICAL DNA VACCINES MARKET BY FUNCTION, THROUGH 2019 (\$ MILLIONS)	125
TABLE 77 GLOBAL VALUE OF DNA VACCINES MARKET, BY GEOGRAPHICAL REGION, THROUGH 2019 (\$ MILLIONS)	126
TABLE 78 MERCK VACCINE PRODUCTS	159
TABLE 79 COMPANIES WITH ACTIVE DNA VACCINE CLINICAL TRIALS	176

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL VALUE OF DNA VACCINE MARKET BY APPLICATION, 2013-2019 (\$ MILLIONS)	7
FIGURE 1 EVOLUTION OF VACCINE TECHNOLOGIES	22
FIGURE 2 MECHANISM OF ACTION OF A DNA VACCINE	25
FIGURE 3 SAFETY AND EFFICACY PROFILE OF DNA VERSUS VIRAL-VECTOR VACCINES	29
FIGURE 4 DNA VACCINE FUNCTION AND MARKET SCOPE	29
FIGURE 5 DNA VACCINE TECHNOLOGY VALUE CHAIN	33
FIGURE 6 CONVENTIONAL AND PLASMID DNA VACCINE PRODUCTION PROCESS	38
FIGURE 7 EP PROCESS SCHEMATIC	41
FIGURE 8 STRATEGIES FOR TARGETING DENDRITIC CELLS	46
FIGURE 9 FUTURE VACCINE CLINICAL TRIALS OVERVIEW	53
FIGURE 10 MARKETING OF APPROVED VACCINES IN THE UNITED STATES, 2014 (%)	84
FIGURE 11 DNA VACCINE COMMERCIAL VALUE CHAIN	89
FIGURE 12 DNA VACCINE STRATEGIC MARKET GRID	109